Canntab—Putting the ‘Medical’ into Medicinal Cannabis

This profile is part of an investor education campaign. The profile provides detailed information which was sourced and approved by Canntab Therapeutics in order to help investors make better investment decisions. The Company’s support of Investing News Network ensures we can continue to bring you unbiased, independent news and information.

Life Science Investing News Featured Stock

Overview

Canntab Therapeutics is bringing pharmaceutical expertise to the cannabis market through the development of its patent-pending Canntab Extended Release (XR) Tablets™. Using proprietary extended release technology previously developed by the company, Canntab is producing a safe, stable and standardized delivery method for cannabis particles (CBD and THC) that is not burdened with the negative effects associated with smoking, edibles or topicals.

The proprietary extended release technology provides lasting effects of 12 to 18 hours, making the Canntab XR Tablets™ an appealing alternative to other intake methods. The XR Tablets™ have

... read more at: https://investingnews.com/company-profiles/cannabis-extended-release-technology-canntab-therapeutics/

by